Unveiling the Synergistic Effects of Q203 and PBTZ169 Against Mycobacterium Tuberculosis: an in-Depth Study

EasyChair Preprint no. 11880

Abstract

Tuberculosis (TB) remains a global health challenge, necessitating continuous exploration of novel treatment regimens. This research delves into the synergistic effects of Q203 and PBTZ169 against Mycobacterium tuberculosis, aiming to uncover innovative strategies for TB therapy. Q203, an ATP synthase inhibitor, and PBTZ169, targeting decaprenyl phosphoryl-beta-D-ribose oxidase (DprE1), exhibit promising individual antibacterial activities.  In vitro, a checkerboard assay revealed a unique synergistic interaction, particularly at one-half the MIC50 of Q203 combined with one-half the MIC50 of PBTZ169. This combination demonstrated a substantial reduction in bacterial growth compared to individual treatments, highlighting its bacteriostatic activity against M. tuberculosis. Further investigations, including the assessment of Q203-resistant mutants, affirm the specificity of the observed synergy, ruling out off-target effects.

Keyphrases: assay, bvc, checkerboard

@Booklet{EasyChair:11880,
  author = {Kurez Oroy and Robert Thomas},
  title = {Unveiling the Synergistic Effects of Q203 and PBTZ169 Against Mycobacterium Tuberculosis: an in-Depth Study},
  howpublished = {EasyChair Preprint no. 11880},

  year = {EasyChair, 2024}}